AAAAAA

   
Results: 1-25 | 26-49 |
Results: 26-49/49
ACUTE DIGOXIN OVERDOSE IN A NEWBORN WITH RENAL-FAILURE - USE OF DIGOXIN IMMUNE FAB AND PERITONEAL-DIALYSIS
Authors: BERKOVITCH M AKILESH MR GERACE R VERJEE Z MCGUIGAN M WHYTE H KOREN G
Citation: M. Berkovitch et al., ACUTE DIGOXIN OVERDOSE IN A NEWBORN WITH RENAL-FAILURE - USE OF DIGOXIN IMMUNE FAB AND PERITONEAL-DIALYSIS, Therapeutic drug monitoring, 16(5), 1994, pp. 531-533
RECENT INCREASES IN NUMBERS AND RISK OF FATALITIES IN YOUNG-CHILDREN INGESTING IRON PREPARATIONS
Authors: BERKOVITCH M MATSUI D LAMM SH ROSA F KOREN G
Citation: M. Berkovitch et al., RECENT INCREASES IN NUMBERS AND RISK OF FATALITIES IN YOUNG-CHILDREN INGESTING IRON PREPARATIONS, Veterinary and human toxicology, 36(1), 1994, pp. 53-55
ARTHROPATHY IN THALASSEMIA PATIENTS RECEIVING DEFERIPRONE
Authors: BERKOVITCH M LAXER RM INMAN R KOREN G PRITZKER KPH FRITZLER MJ OLIVIERI NF
Citation: M. Berkovitch et al., ARTHROPATHY IN THALASSEMIA PATIENTS RECEIVING DEFERIPRONE, Lancet, 343(8911), 1994, pp. 1471-1472
CRITICAL COMPARISON OF NOVEL AND EXISTING METHODS OF COMPLIANCE ASSESSMENT DURING A CLINICAL-TRIAL OF AN ORAL IRON CHELATOR
Authors: MATSUI D HERMANN C KLEIN J BERKOVITCH M OLIVIERI N KOREN G
Citation: D. Matsui et al., CRITICAL COMPARISON OF NOVEL AND EXISTING METHODS OF COMPLIANCE ASSESSMENT DURING A CLINICAL-TRIAL OF AN ORAL IRON CHELATOR, Journal of clinical pharmacology, 34(9), 1994, pp. 944-949
SAFETY OF QUINOLONES IN PREGNANCY
Authors: BERKOVITCH M PASTUSZAK A GAZARIAN M LEWIS M KOREN G
Citation: M. Berkovitch et al., SAFETY OF QUINOLONES IN PREGNANCY, Pediatric research, 35(4), 1994, pp. 10000091-10000091
NEED FOR EARLY, LOW-DOSE CHELATION-THERAPY IN YOUNG-CHILDREN WITH TRANSFUSED HOMOZYGOUS BETA-THALASSEMIA (HBT)
Authors: BERKOVITCH M BRITTENHAM GM KOREN G OLIVIERI NF
Citation: M. Berkovitch et al., NEED FOR EARLY, LOW-DOSE CHELATION-THERAPY IN YOUNG-CHILDREN WITH TRANSFUSED HOMOZYGOUS BETA-THALASSEMIA (HBT), Pediatric research, 35(4), 1994, pp. 10000157-10000157
REDUCTION IN HEPATIC IRON STORES WITH THE ORAL IRON CHELATOR-L1 IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT THALASSEMIA (HBT) AND SICKLE-CELL DISEASE (SCD) - 1ST 3 YEARS OF THE CANADIAN TRIAL
Authors: BERKOVITCH M OLIVIERI NF BRITTENHAM GM KOREN G
Citation: M. Berkovitch et al., REDUCTION IN HEPATIC IRON STORES WITH THE ORAL IRON CHELATOR-L1 IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT THALASSEMIA (HBT) AND SICKLE-CELL DISEASE (SCD) - 1ST 3 YEARS OF THE CANADIAN TRIAL, Pediatric research, 35(4), 1994, pp. 10000158-10000158
DETAILED INVESTIGATION OF IMMUNE FUNCTION IN PATIENTS (PTS) RECEIVINGTHE IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE (L1) - NO EVIDENCE OF ABNORMALITY AFTER 3 YEARS OF THERAPY
Authors: BERKOVITCH M MEYDAN N DONSKY J COLLINS AF SHER GD MATSUI D KOREN G HACKMAN R ROIFMAN C OLIVIERI NF
Citation: M. Berkovitch et al., DETAILED INVESTIGATION OF IMMUNE FUNCTION IN PATIENTS (PTS) RECEIVINGTHE IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE (L1) - NO EVIDENCE OF ABNORMALITY AFTER 3 YEARS OF THERAPY, Pediatric research, 35(4), 1994, pp. 10000158-10000158
SAFETY OF THE NEW QUINOLONES IN PREGNANCY
Authors: BERKOVITCH M PASTUSZAK A GAZARIAN M LEWIS M KOREN G
Citation: M. Berkovitch et al., SAFETY OF THE NEW QUINOLONES IN PREGNANCY, Obstetrics and gynecology, 84(4), 1994, pp. 535-538
MORPHINE IN KIDNEY FAILURE
Authors: BERKOVITCH M ITO S SHEAR NH KOREN G
Citation: M. Berkovitch et al., MORPHINE IN KIDNEY FAILURE, Clinical pharmacology and therapeutics, 56(1), 1994, pp. 114-114
REDUCTION IN HEPATIC IRON STORES WITH THE ORAL IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE (L1) IN PATIENTS (PTS) WITH TRANSFUSION DEPENDENT THALASSEMIA (HBT) AND SICKLE-CELL DISEASE (SCD)
Authors: MATSUI D BERKOVITCH M OLIVIERI N KOREN G
Citation: D. Matsui et al., REDUCTION IN HEPATIC IRON STORES WITH THE ORAL IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE (L1) IN PATIENTS (PTS) WITH TRANSFUSION DEPENDENT THALASSEMIA (HBT) AND SICKLE-CELL DISEASE (SCD), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 175-175
PHARMACOKINETICS (PK) OF (IV) INTRAVENOUS ARGININE BUTYRATE (AB) IN HEMOGLOBINOPATHY PATIENTS (PTS)
Authors: MATSUI D BERKOVITCH M SHER GD HADZIALIC G OLIVIERI N ITO S DONSKY J KOREN G
Citation: D. Matsui et al., PHARMACOKINETICS (PK) OF (IV) INTRAVENOUS ARGININE BUTYRATE (AB) IN HEMOGLOBINOPATHY PATIENTS (PTS), Clinical pharmacology and therapeutics, 55(2), 1994, pp. 175-175
FACTORS INFLUENCING THE ACQUISITION AND SEVERITY OF YERSINIA-ENTEROCOLITICA INFECTION IN PATIENTS WITH THALASSEMIA
Authors: ADAMKIEWICZ T POLSINELLI K BERKOVITCH M KRISHNAN C OLIVIERI NF
Citation: T. Adamkiewicz et al., FACTORS INFLUENCING THE ACQUISITION AND SEVERITY OF YERSINIA-ENTEROCOLITICA INFECTION IN PATIENTS WITH THALASSEMIA, Blood, 84(10), 1994, pp. 10000258-10000258
THE 1ST PROSPECTIVE RANDOMIZED TRIAL OF SUBCUTANEOUS DEFEROXAMINE ANDTHE ORALLY-ACTIVE IRON-CHELATING AGENT L1
Authors: OLIVIERI NF SHER GD MACKINNON JA POPE I ENTSUAH B SNIDER MA LEWIS N SHAW D BERKOVITCH M KOREN G BRITTENHAM GM
Citation: Nf. Olivieri et al., THE 1ST PROSPECTIVE RANDOMIZED TRIAL OF SUBCUTANEOUS DEFEROXAMINE ANDTHE ORALLY-ACTIVE IRON-CHELATING AGENT L1, Blood, 84(10), 1994, pp. 10000363-10000363
EXPERIENCE WITH MISOPROSTOL THERAPY FOR NONSTEROIDAL ANTIINFLAMMATORYDRUG (NSAID) GASTROPATHY IN CHILDREN
Authors: GAZARIAN M BERKOVITCH M KOREN G SILVERMAN ED LAXER RM
Citation: M. Gazarian et al., EXPERIENCE WITH MISOPROSTOL THERAPY FOR NONSTEROIDAL ANTIINFLAMMATORYDRUG (NSAID) GASTROPATHY IN CHILDREN, Arthritis and rheumatism, 37(6), 1994, pp. 180000040-180000040
GANCICLOVIR IN NEWBORNS
Authors: BERKOVITCH M MATSUI D OH P SHEAR NH KOREN G
Citation: M. Berkovitch et al., GANCICLOVIR IN NEWBORNS, Clinical pharmacology and therapeutics, 54(6), 1993, pp. 683-683
INTRAVENOUS (IV) INFUSION OF ARGININE BUTYRATE (AB) INCREASES GAMMA-GLOBIN MESSENGER-RNA EXPRESSION AND F-RETICULOCYTES IN PATIENTS (PTS) WITH HOMOZYGOUS BETA-THALASSEMIA (HBT) AND SICKLE-CELL DISEASE (SCD)
Authors: SHER GD ENTSUAH B GINDER G DOVER G LITTLE J DONSKY J BERKOVITCH M LEWIS N CHANG L PERRINE S OLIVIERI NF
Citation: Gd. Sher et al., INTRAVENOUS (IV) INFUSION OF ARGININE BUTYRATE (AB) INCREASES GAMMA-GLOBIN MESSENGER-RNA EXPRESSION AND F-RETICULOCYTES IN PATIENTS (PTS) WITH HOMOZYGOUS BETA-THALASSEMIA (HBT) AND SICKLE-CELL DISEASE (SCD), Blood, 82(10), 1993, pp. 10000312-10000312
DIFFERENTIAL IRON DEPOSITION IN THE ANTERIOR-PITUITARY (AP) AND LIVERIN HOMOZYGOUS BETA-THALASSEMIA (HBT) - PREDICTION OF GONADAL FAILURE BY MAGNETIC-RESONANCE-IMAGING (MRI)
Authors: BERKOVITCH M MILONE S KUCHARCZYK W LIU P PAPADOURIS D COLLINS AF OLIVIERI NF
Citation: M. Berkovitch et al., DIFFERENTIAL IRON DEPOSITION IN THE ANTERIOR-PITUITARY (AP) AND LIVERIN HOMOZYGOUS BETA-THALASSEMIA (HBT) - PREDICTION OF GONADAL FAILURE BY MAGNETIC-RESONANCE-IMAGING (MRI), Blood, 82(10), 1993, pp. 10000359-10000359
NEED FOR EARLY, LOW-DOSE CHELATION-THERAPY IN YOUNG-CHILDREN WITH TRANSFUSED HOMOZYGOUS BETA-THALASSEMIA (HBT)
Authors: BERKOVITCH M COLLINS AF PAPADOURIS D WESSON D SIRNA JB BRITTENHAM GM OLIVIERI NF
Citation: M. Berkovitch et al., NEED FOR EARLY, LOW-DOSE CHELATION-THERAPY IN YOUNG-CHILDREN WITH TRANSFUSED HOMOZYGOUS BETA-THALASSEMIA (HBT), Blood, 82(10), 1993, pp. 10000359-10000359
HEPATITIS-C VIRUS (HCV) INFECTION IN TRANSFUSED PATIENTS (PTS) WITH BETA-HEMOGLOBINOPATHIES ACCELERATES IRON-INDUCED HEPATIC DAMAGE
Authors: SHER GD MILONE SD CAMERON R JAMIESON FB KRAJDEN M COLLINS AF MATSUI D ENTSUAH B BERKOVITCH M HACKMAN R FRANCOMBE WH OLIVIERI NF
Citation: Gd. Sher et al., HEPATITIS-C VIRUS (HCV) INFECTION IN TRANSFUSED PATIENTS (PTS) WITH BETA-HEMOGLOBINOPATHIES ACCELERATES IRON-INDUCED HEPATIC DAMAGE, Blood, 82(10), 1993, pp. 10000360-10000360
DETAILED INVESTIGATION OF IMMUNE FUNCTION IN PATIENTS (PTS) RECEIVINGTHE IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE (L1) - NO EVIDENCE OF ABNORMALITY AFTER 3 YEARS OF THERAPY
Authors: BERKOVITCH M MEYDAN N DONSKY J COLLINS AF SHER GD MATSUI D KOREN G HACKMAN R ROIFMAN C OLIVIERI NF
Citation: M. Berkovitch et al., DETAILED INVESTIGATION OF IMMUNE FUNCTION IN PATIENTS (PTS) RECEIVINGTHE IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE (L1) - NO EVIDENCE OF ABNORMALITY AFTER 3 YEARS OF THERAPY, Blood, 82(10), 1993, pp. 10000360-10000360
THE IMAGING OF CARDIAC IRON IN TRANSFUSION DEPENDENT DISEASES PATIENTS - STILL AN UNCERTAIN SCIENCE
Authors: HACKMAN R SHER GD MILONE SD LIU PP BERKOVITCH M PAPADOURIS D COLLINS AF OLIVIERI NF
Citation: R. Hackman et al., THE IMAGING OF CARDIAC IRON IN TRANSFUSION DEPENDENT DISEASES PATIENTS - STILL AN UNCERTAIN SCIENCE, Blood, 82(10), 1993, pp. 10000470-10000470
RHEUMATIC MANIFESTATIONS IN PATIENTS WITH HOMOZYGOUS BETA-THALASSEMIA(HBT) MAJOR
Authors: MUHANNA A BERKOVITCH M COLLINS A MATSUI D OLIVIERI N INMAN R
Citation: A. Muhanna et al., RHEUMATIC MANIFESTATIONS IN PATIENTS WITH HOMOZYGOUS BETA-THALASSEMIA(HBT) MAJOR, Arthritis and rheumatism, 36(9), 1993, pp. 190000115-190000115
RHEUMATIC MANIFESTATIONS IN PATIENTS WITH HOMOZYGOUS BETA-THALASSEMIA(HBT) MAJOR
Authors: MUHANNA A BERKOVITCH M COLLINS A MATSUI D OLIVIERI N INMAN R
Citation: A. Muhanna et al., RHEUMATIC MANIFESTATIONS IN PATIENTS WITH HOMOZYGOUS BETA-THALASSEMIA(HBT) MAJOR, Arthritis and rheumatism, 36(5), 1993, pp. 32-32
Risultati: 1-25 | 26-49 |